DEFA14A: Walgreens Boots Alliance to be Acquired by Sycamore Partners, Taking Company Private

Walgreens Boots Alliance (WBA) has entered into an agreement to be acquired by Sycamore Partners, a private equity firm, with the transaction expected to close in the fourth quarter of calendar year 2025, pending regulatory and shareholder approvals.

Summary

• Walgreens Boots Alliance (WBA) has agreed to be acquired by Sycamore Partners, a private equity firm, in a deal that will take the company private.
• The agreement includes WBA's international businesses, including Boots and No7 Beauty Company.
• The transaction is expected to close in the fourth quarter of calendar year 2025, subject to regulatory and shareholder approvals.
• Stefano Pessina will reinvest in the acquiring company and remain a significant owner alongside Sycamore Partners.
• WBA will maintain its headquarters in the Chicago area, while Boots and No7 Beauty Company will remain headquartered in Nottingham, London, and Dublin.
• The company emphasizes that it will continue to operate with excellence as a public company until the transaction closes.
• Sycamore Partners has a history of collaborating with management teams and investing in retailers navigating change.
• The company assures stakeholders that current agreements will remain in place and there will be no immediate changes to day-to-day operations.
• WBA is filing a definitive proxy statement on Schedule 14A and a transaction statement on Schedule 13E-3 with the SEC regarding the proposed transaction.
• Shareholders with vested shares in WBA will receive $11.45 in cash per share upon close, as well as the right to receive up to $3.00 in cash per share from future monetization of the VillageMD business.

Sentiment

Score: 7

Explanation: The document conveys a moderately positive sentiment, emphasizing the benefits of the acquisition by Sycamore Partners and the continuation of WBA's transformation strategy. While acknowledging potential risks, the overall tone is optimistic and forward-looking.

Positives

• Sycamore Partners has a history of collaborating with management teams and brings expertise in business transformation.
• The acquisition is expected to provide WBA with increased agility in a private company framework.
• Stefano Pessina's continued involvement ensures continuity and alignment of interests.
• Sycamore's investment reflects confidence in WBA's international businesses and their role in the community.
• The company's transformation strategy is expected to continue with Sycamore's support.
• The company's headquarters will remain in their current locations.

Negatives

• The transaction is subject to regulatory and shareholder approvals, creating uncertainty about its completion.
• There are restrictions during the pendency of the proposed transaction that may impact the Company's ability to pursue certain business opportunities or strategic transactions.
• The company is pausing speaking engagements to ensure consistent external messaging on the transaction.

Risks

• The proposed transaction may not be completed in a timely manner or at all.
• Sycamore Partners may fail to obtain the necessary financing arrangements.
• The failure to satisfy conditions to the consummation of the proposed transaction, including regulatory and stockholder approval, could prevent the deal from closing.
• An event, change, or circumstance could give rise to the termination of the transaction agreements.
• The announcement or pendency of the proposed transaction could negatively affect WBA's business relationships and operating results.
• The proposed transaction could disrupt WBA's current plans and operations.
• WBA may face challenges in retaining and hiring key personnel and maintaining relationships with key business partners and customers.
• Management's attention could be diverted from WBA's ongoing business operations.
• Significant or unexpected costs, charges, or expenses could result from the proposed transaction.
• Potential litigation relating to the proposed transaction could be instituted against the parties.
• Uncertainties related to the continued availability of capital and financing and rating agency actions could arise.
• Holders of Divested Asset Proceed Rights may receive less-than-anticipated payments or no payments.
• Adverse general and industry-specific economic and market conditions could impact the transaction.

Future Outlook

The company anticipates that operating as a private company will enable it to continue to execute and accelerate its transformation plan and further enhance the customer, patient, and team member experience.

Management Comments

• We are confident that Sycamore is the right partner for us as we continue our transformation.
• Sycamore has shown a great interest and belief in our International businesses and appreciation for our talented team members.
• We will remain focused on our transformation: to further strengthen our position as the leading UK and Ireland beauty business winning market share and new customers, evolving our pharmacy business into a leading patient-focused healthcare business, and enhancing our digital experience and store estate.

Industry Context

Private equity firms are increasingly investing in the retail and healthcare sectors, seeking to leverage their operational expertise and financial resources to drive growth and improve profitability. This acquisition aligns with that trend, as Sycamore Partners aims to support WBA's transformation and enhance its market position.

Comparison to Industry Standards

• Sycamore Partners has a track record of successful investments in retailers navigating change, including companies such as Staples, Talbots, Ann Taylor/LOFT and RONA (formerly Lowes Canada).
• Other comparable companies that have been taken private by private equity firms include Neiman Marcus, Toys 'R' Us, and Claire's.
• These transactions often involve operational improvements, cost reductions, and strategic repositioning to enhance long-term value.

Stakeholder Impact

• Shareholders will receive cash for their shares and a potential additional payment from the monetization of VillageMD.
• Employees are assured that there will be no immediate changes to their compensation, benefits, or roles.
• Customers and patients can continue to shop or visit WBA stores as they do today.
• The company will continue to contribute to the communities in which it operates.

Next Steps

• WBA will file a definitive proxy statement on Schedule 14A and a transaction statement on Schedule 13E-3 with the SEC.
• The transaction is subject to shareholder approval and regulatory approvals.
• The company will continue to operate as a public company until the transaction closes in the fourth quarter of calendar year 2025.
• WBA will communicate directly with team members and stakeholders as key milestones are reached.

Key Dates

Keywords

Sycamore Partners, Walgreens Boots Alliance, acquisition, private equity, Boots, No7 Beauty Company, transaction, stakeholders, pharmacy, retail